Deal Team

Corporate
Executive Compensation and Benefits
Intellectual Property
Litigation
Finance
Real Estate M&A
Tax

AbbVie in its $10.1 billion acquisition of ImmunoGen

AbbVie Inc. (NYSE: ABBV) and ImmunoGen, Inc. (NASDAQ: IMGN) today announced a definitive agreement under which AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE®, for $31.26 per share in cash, for a total equity value of approximately $10.1 billion.

Wachtell, Lipton, Rosen & Katz is serving as legal advisor to AbbVie.